Roivant bumps stake in Im­muno­vant with a $200M deal. But with M&A off the ta­ble, shares crater

Roivant has worked out a deal to pick up a chunk of stock in its ma­jor­i­ty-owned sub Im­muno­vant $IMVT, but the stock buy falls far short of its much-dis­cussed thoughts about buy­ing out all of the 43% of shares it doesn’t al­ready own.

Roivant, which re­cent­ly inked a SPAC move to the mar­ket at a $7 bil­lion-plus val­u­a­tion, has forged a deal to boost its own­er­ship in Im­muno­vant by 6.3 points, end­ing with 63.8% of the biotech’s stock fol­low­ing a $200 mil­lion in­jec­tion. That cash will bol­ster Im­muno­vant’s cash re­serves, giv­ing it a $600 mil­lion war chest to fund a slate of late-stage stud­ies for its big drug: the an­ti-FcRn an­ti­body IMVT-1401.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER